Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion

Changes in the levels of enkephalin and substance P messenger RNA expression were examined in the striatum following dopamine depletion resulting from unilateral injection of 6-hydroxydopamine into the substantia nigra. In response to striatal dopamine depletion, the levels of enkephalin messenger RNA were elevated, whereas substance P messenger RNA was decreased within all regions of the striatum. Examination of the striatal peptide messenger RNAs between one and 21 days after the injection of 6-hydroxydopamine revealed a temporal dissociation between changes in enkephalin and substance P messenger RNAs. Within one day of the 6-hydroxydopamine injection, substance P messenger RNA was significantly decreased by 30% at all levels of the striatum. This decrease was maintained for up to 21 days after the lesion. In contrast, striatal enkephalin messenger RNA was not significantly elevated until three days following the injection of 6-hydroxydopamine, after which there was a gradual increase up to 21 days. In order to correlate alterations in peptide messenger RNA expression with 6-hydroxydopamine-induced changes in striatal dopamine innervation, tissue punches from the striatum were examined for dopamine content at one, two, three and seven days after the lesion. One day after the lesion, striatal dopamine levels were significantly increased by 47%. In contrast, within two days tissue dopamine content was reduced by 77% compared to control levels. A further decrease of 90% or more was observed at three and seven days after the lesion. Taken together, these data demonstrate a temporal dissociation between changes in enkephalin and substance P messenger RNA levels following 6-hydroxydopamine-induced striatal dopamine depletions. This temporal dissociation may reflect a differential response of enkephalin and substance P messenger RNAs to alterations in dopamine release and subsequent receptor activation.

[1]  E. Abercrombie,et al.  Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats , 1990, Brain Research.

[2]  M. Zigmond,et al.  High‐and Low‐Affinity States of Striatal D2 Receptors Are Not Affected by 6‐Hydroxydopamine or Chronic Haloperidol Treatment , 1984, Journal of neurochemistry.

[3]  D. Kooy,et al.  Organization of the striatum: Collateralization of its Efferent Axons , 1985, Brain Research.

[4]  J. Angulo.  Involvement of Dopamine D1 and D2 Receptors in the Regulation of Proenkephalin mRNA Abundance in the Striatum and Accumbens of the Rat Brain , 1992, Journal of neurochemistry.

[5]  J. Mallet,et al.  Complete coding sequence of rat tyrosine hydroxylase mRNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Woolley,et al.  Effect of Chronic Typical and Atypical Neuroleptic Treatment on Proenkephalin mRNA Levels in the Striatum and Nucleus Accumbens of the Rat , 1990, Journal of neurochemistry.

[7]  J. McGinty,et al.  Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes , 1990, Brain Research.

[8]  C. Feuerstein,et al.  Similar Time Course Changes in Striatal Levels of Glutamic Acid Decarboxylase and Proenkephalin mRNA Following Dopaminergic Deafferentation in the Rat , 1988, Journal of neurochemistry.

[9]  M. Sole,et al.  A simple specific radioenzymatic assay for the simultaneous measurement of picogram quantities of norepinephrine, epinephrine, and dopamine and in plasma and tissues. , 1977, Biochemical medicine.

[10]  R. M. Beckstead,et al.  Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat , 1986, Neuroscience.

[11]  R. Roth,et al.  Effect of impulse flow on the release and synthesis of dopamine in the striatum , 1973 .

[12]  V. Höllt,et al.  Differential dopaminergic regulation of proenkephalin and prodynorphin mRNAs in the basal ganglia of rats. , 1992, Brain research. Molecular brain research.

[13]  Ian Q. Whishaw,et al.  Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats , 1988, Brain Research.

[14]  M. Caron,et al.  Molecular cloning and expression of the gene for a human D1 dopamine receptor , 1990, Nature.

[15]  M. Zigmond,et al.  Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.

[16]  M. Schumacher,et al.  Regulation by dopaminergic neurotransmission of dopamine D2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. , 1991, Brain research. Molecular brain research.

[17]  Localization and pharmacology of some dopamine receptor complexes in the striatum and the pituitary gland: synaptic and son-synaptic communication. , 1988 .

[18]  H. Tilson,et al.  Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. , 1990, Brain research. Molecular brain research.

[19]  H. Groenewegen,et al.  Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions , 1987, Brain Research.

[20]  M. Zigmond,et al.  Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. , 1989, International review of neurobiology.

[21]  T. Powell,et al.  The structure of the caudate nucleus of the cat: light and electron microscopy. , 1971, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[22]  K. Yoshikawa,et al.  Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system. , 1984, The Journal of biological chemistry.

[23]  J. Nilsson,et al.  Dopamine D2 receptor binding sites for agonists. A tetrahedral model. , 1985, Molecular pharmacology.

[24]  T. Robinson,et al.  Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  L. Iversen,et al.  Time course of the effects of 6‐hydroxydopamine on catecholamine‐containing neurones in rat hypothalamus and striatum , 1970, British journal of pharmacology.

[26]  P J Elliott,et al.  Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. , 1987, Brain research.

[27]  U. Ungerstedt,et al.  Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. , 1971, European journal of pharmacology.

[28]  J. Cadet,et al.  Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat , 1990, Neuroscience Letters.

[29]  C. Gerfen,et al.  Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study , 1988, Brain Research.

[30]  Philip M. Groves,et al.  Dopamine receptor changes following destruction of the nigrostriatal pathway: Lack of a relationship to rotational behavior , 1981, Brain Research.

[31]  C. Wilson,et al.  Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  J. Peuler,et al.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. , 1977, Life sciences.

[33]  C. Gerfen,et al.  Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  A. Parent,et al.  The striatopallidal and striatonigral projections: two distinct fiber systems in primate , 1984, Brain Research.

[35]  C. Altar,et al.  Time Course of Adaptations in Dopamine Biosynthesis, Metabolism, and Release Following Nigrostriatal Lesions: Implications for Behavioral Recovery from Brain Injury , 1987, Journal of neurochemistry.

[36]  S. Snyder,et al.  Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.

[37]  J. Hollerman,et al.  Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons , 1992, Neuroscience.

[38]  M. E. Lewis,et al.  High-resolution in situ hybridization histochemistry. , 1989, Methods in enzymology.

[39]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[40]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[41]  H. Kita,et al.  Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations , 1988, Brain Research.

[42]  D. Haverstick,et al.  Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. , 1989, The Journal of pharmacology and experimental therapeutics.

[43]  C. Auffray,et al.  Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons , 1988, Brain Research.

[44]  T. Bonner,et al.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. T. Kitai,et al.  Single neostriatal efferent axons in the globus pallidus: a light and electron microscopic study. , 1981, Science.

[46]  R. Roth,et al.  Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway. , 1973, The Journal of pharmacology and experimental therapeutics.